Sanofi launches iPhone glucose meter; St. Jude puts positive spin on aborted Fame II trial;

 @FierceMedDev: Folks, the clock is ticking. Get your nominations in for the 15 fiercest device developers. Survey | Follow @FierceMedDev

> Sanofi ($SNY) and AgaMatrix have launched their iPhone-compatible blood glucose meter, iBGStar. The device is available at Apple stores and Walgreens locations. News

> St. Jude Medical ($STJ) says the data from its aborted Fame II trial demonstrate that fractional flow reserve-guided therapies lead to substantially lower need for revascularization among patients with stable coronary artery disease than with traditional treatment. Story

> Boston Scientific ($BSX) generated promising results from its Reprise I feasibility trial, which tested the safety of its Lotus aortic valve system in patients with severe aortic valve disease. Release

> Axiomed has received CE mark approval for Freedom, its elastomeric spinal disc replacement device. Now that the device can be marketed in Europe, the company is planning to seek FDA approval stateside. Release

> Crimson Life Sciences is collecting donated medical devices for humanitarian efforts in Syria, as part of the Save Syrian Lives campaign. The company put out a list of most-needed devices, including portable X-rays, defibrillators and sterilization ovens. Article

> Norway's DiaGeneic gained a major federal grant toward development of diagnostics tests for the early detection of Alzheimer's disease. Release

Pharma News

 @FiercePharma: Italy's Rovati family finds partners w/cash: Rottapharm sells 50% stake to private equity firms--BloombergStory | Follow @FiercePharma

> Payers likely to throw up hurdles to Pfizer's new RA drug. More

> Big-name pharmas peer at Amylin's books to prep for bids. News

> Private equity firms snap up 50% of Rottapharm. Story

Biotech News

 @FierceBiotech: Mobile apps could rival pharma's crown jewels. More | Follow @FierceBiotech

 @RyanMFierce: Interesting case for why mobile health apps could compete with drugs and hurt pharma by @chasedaveAnalysis | Follow @RyanMFierce

 @JohnCFierce: New chief takes helm at Promedior (fibrosis) and steers a course for Boston. More | Follow @JohnCFierce

> First wave of AstraZeneca's CNS R&D group gets the ax. Story

> Newron soars on positive PhIII results, $26M pact for Parkinson's drug. Article

> Buzz: Big Pharma suitors line up for a look at Amylin's books. News

Pharma Manufacturing News

> U.K. pharmacy group wants drug exports stopped. Story

> Merck KGaA says cuts will save $385 million. News

> Pakistan's ephedrine scandal takes on international intrigue. Article

Biotech Research News

> Scientist uses stem cells to rebuild bone. News

> How do you make a deaf mouse hear? Emory University tries gene therapy. More

> Compounds may combat cancers by reversing p53 mutation. Article

And Finally... The New York Times writes on how mobile health devices and technology are drastically changing how health care is delivered in the developing world. Story

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.